Sarah P. Cohen Alexandria L. Miller, Saurabh Rajpal, Scott H. Visovatti
Ohio State University School of Medicine and Nationwide Children’s Hospital.
United States
Heart Failure Clinics
Heart Fail Clin 2026; 22: 371-385
DOI: 10.1016/j.hfc.2026.02.011
Abstract
Significant progress has been made in the management of pulmonary hypertension (PH), and especially pulmonary arterial hypertnesion (PAH), over the last 3 decades. Recent advances in the diagnosis, risk stratification, and treatment of the disease have resulted in improved outcomes. However, patients with PAH continue to experience significant morbidity and mortality. Thus, continued research efforts are needed in order to develop risk stratification models and therapies that take into account more individualized patient-specific factors.
Category
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease or Adult Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No